Pore-forming small molecules offer a promising way to tackle cystic fibrosis

In cystic fibrosis, ion-transport abnormalities cause problems in many organs. A small molecule that forms cell-membrane pores allowing ion transport shows therapeutic promise in human cells and a model of the disease.
David N. Sheppard is in the School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UK.

Search for this author in:

Anthony P. Davis is in the School of Chemistry, University of Bristol, Bristol BS8 4LN, UK.

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature 567, 315-317 (2019)

doi: 10.1038/d41586-019-00781-y


  1. 1.

    Ratjen, F. et al. Nature Rev. Dis. Primers 1, 15010 (2015).

  2. 2.

    Muraglia, K. A. et al. Nature 567, 405–408 (2019).

  3. 3.

    Davies, J. C. et al. N. Engl. J. Med. 379, 1599–1611 (2018).

  4. 4.

    Keating, D. et al. N. Engl. J. Med. 379, 1612–1620 (2018).

  5. 5.

    Mall, M. A. & Galietta, L. J. V. J. Cystic Fibros. 14, 561–570 (2015).

  6. 6.

    Shen, B., Li, X., Wang, F., Yao, X. & Yang, D. PLoS ONE 7, e34694 (2012).

  7. 7.

    Li, H. et al. Nature Chem. 8, 24–32 (2016).

  8. 8.

    Stoltz, D. A., Meyerholz, D. K. & Welsh, M. J. N. Engl. J. Med. 372, 351–362 (2015).

  9. 9.

    Quinton, P. M. Am. J. Physiol. Cell Physiol. 299, C1222–C1233 (2010).

  10. 10.

    Anderson, T. M. et al. Nature Chem. Biol. 10, 400–406 (2014).

  11. 11.

    Cioffi, A. G., Hou, J., Grillo, A. S., Diaz, K. A. & Burke, M. D. J. Am. Chem. Soc. 137, 10096–10099 (2015).

  12. 12.

    Grillo, A. S. et al. Science 356, 608–616 (2017).

  13. 13.

    Diamond, J. M. Nature 300, 683–685 (1982).

Download references

Competing Financial Interests

D.N.S. is the recipient of a Vertex Innovation Award funded by Vertex Pharmaceuticals. The awards are administered by Chameleon, a medical communications company. Vertex Innovation Awards are reviewed by a grant-awarding panel, which selects reviewers to assess the applications and makes a final decision based on the comments of peer reviewers. Members of the grant-awarding panel and peer reviewers are academics and/or clinicians independent of Vertex Pharmaceuticals.

Nature Briefing

Sign up for the daily Nature Briefing email newsletter

Stay up to date with what matters in science and why, handpicked from Nature and other publications worldwide.

Sign Up